Biocon Q3FY18 Revenue at Rs 1092 Crore

28
Biocon Q3FY18 Revenue

Biocon Ltd, Asia’s premier biopharmaceuticals company, today announced its consolidated financial results for the fiscal third quarter ended on December 31st, 2017.

Commenting on the highlights, Chairperson & Managing Director, Kiran Mazumdar-Shaw stated:  “This has been a significant quarter for Biocon as we crossed a major milestone of obtaining USFDA approval for biosimilar Trastuzumab partnered with Mylan. Another highlight was the announcement of a new strategic partnership with Sandoz to develop, manufacture and commercialize a portfolio of next wave of biosimilars for global markets.

SIGN UP FOR OUR EMAIL NEWSLETTER
Health tips, wellness advice and more.
We respect your privacy

Our Branded Formulations and Research Services segments reported a healthy double-digit growth during this quarter. We expect growth in other segments to revive from early next fiscal.”

 

Highlights:

  • Biocon becomes the first Company from India to get its biosimilar approved by the USFDA; OgivriTM, co-developed by Biocon and Mylan, is also the first biosimilar Trastuzumab to be approved in the US.
  • Biocon collaborates with Sandoz for a global partnership to develop, manufacture and commercialize a number of next generation biosimilars to enhance patient access to complex bio-therapeutics in the area of immunology and oncology.
  • Biocon also receives approval from ANVISA, the Brazilian regulatory agency, for biosimilar Trastuzumab, the first biosimilar Trastuzumab to be approved in Brazil.
  • Biocon launches KRABEVA®, a biosimilar Bevacizumab in India, for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers.
  • EMA accepts the resubmission of Marketing Authorization Applications for Biocon and Mylan’s proposed biosimilars of Trastuzumab and Pegfilgrastim.